全文获取类型
收费全文 | 12653篇 |
免费 | 994篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 68篇 |
儿科学 | 539篇 |
妇产科学 | 288篇 |
基础医学 | 1667篇 |
口腔科学 | 112篇 |
临床医学 | 2111篇 |
内科学 | 2275篇 |
皮肤病学 | 125篇 |
神经病学 | 1216篇 |
特种医学 | 239篇 |
外科学 | 1082篇 |
综合类 | 135篇 |
一般理论 | 29篇 |
预防医学 | 1634篇 |
眼科学 | 222篇 |
药学 | 845篇 |
中国医学 | 21篇 |
肿瘤学 | 1063篇 |
出版年
2023年 | 137篇 |
2022年 | 169篇 |
2021年 | 327篇 |
2020年 | 268篇 |
2019年 | 389篇 |
2018年 | 378篇 |
2017年 | 307篇 |
2016年 | 326篇 |
2015年 | 337篇 |
2014年 | 437篇 |
2013年 | 682篇 |
2012年 | 1028篇 |
2011年 | 1000篇 |
2010年 | 527篇 |
2009年 | 467篇 |
2008年 | 851篇 |
2007年 | 844篇 |
2006年 | 828篇 |
2005年 | 760篇 |
2004年 | 701篇 |
2003年 | 617篇 |
2002年 | 628篇 |
2001年 | 96篇 |
2000年 | 63篇 |
1999年 | 121篇 |
1998年 | 130篇 |
1997年 | 100篇 |
1996年 | 107篇 |
1995年 | 99篇 |
1994年 | 70篇 |
1993年 | 66篇 |
1992年 | 52篇 |
1991年 | 60篇 |
1990年 | 46篇 |
1989年 | 36篇 |
1988年 | 46篇 |
1987年 | 43篇 |
1986年 | 32篇 |
1985年 | 32篇 |
1984年 | 33篇 |
1983年 | 36篇 |
1982年 | 37篇 |
1981年 | 37篇 |
1980年 | 38篇 |
1979年 | 23篇 |
1978年 | 25篇 |
1976年 | 17篇 |
1975年 | 25篇 |
1974年 | 23篇 |
1973年 | 26篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Breanne E. Kunstler Jill L. Cook Joanne L. Kemp Paul D. O’Halloran Caroline F. Finch 《Journal of Science and Medicine in Sport》2019,22(1):2-10
Objectives
To determine: (i) the behaviour change techniques used by a sample of Australian physiotherapists to promote non-treatment physical activity; and (ii) whether those behaviour change techniques are different to the techniques used to encourage adherence to rehabilitation exercises.Design
Cross-sectional survey.Method
An online self-report survey was advertised to private practice and outpatient physiotherapists treating patients with musculoskeletal conditions. The use of 50 behaviour change techniques were measured using five-point Likert-type scale questions.Results
Four-hundred and eighty-six physiotherapists responded to the survey, with 216 surveys fully completed. Most respondents (85.1%) promoted non-treatment physical activity often or all of the time. Respondents frequently used 29 behaviour change techniques to promote non-treatment physical activity or encourage adherence to rehabilitation exercises. A similar number of behaviour change techniques was frequently used to encourage adherence to rehabilitation exercises (n = 28) and promote non-treatment physical activity (n = 26). Half of the behaviour change techniques included in the survey were frequently used for both promoting non-treatment physical activity and encouraging adherence to rehabilitation exercises (n = 25). Graded tasks was the most, and punishment was the least, frequently reported technique used to promote non-treatment physical activity and encourage adherence to rehabilitation exercises.Conclusions
Respondents reported using similar behaviour change techniques to promote non-treatment physical activity and encourage adherence to rehabilitation exercises. The variability in behaviour change technique use suggests the behaviour the physiotherapist is promoting influences their behaviour change technique choice. Including the frequently-used behaviour change techniques in non-treatment physical activity promotion interventions might improve their efficacy. 相似文献2.
3.
4.
A mixed‐method study of effects of a therapeutic play intervention for children on parental anxiety and parents' perceptions of the intervention 下载免费PDF全文
5.
6.
Catherine L. Omosule Dominique Joseph Brooke Weiler Victoria L. Gremminger Spencer Silvey Youngjae Jeong Ashique Rafique Pamela Krueger Sandra Kleiner Charlotte L. Phillips 《Journal of bone and mineral research》2022,37(5):938-953
Osteogenesis imperfecta (OI) is a collagen-related bone disorder characterized by fragile osteopenic bone and muscle weakness. We have previously shown that the soluble activin receptor type IIB decoy (sActRIIB) molecule increases muscle mass and improves bone strength in the mild to moderate G610C mouse model of OI. The sActRIIB molecule binds multiple transforming growth factor-β (TGF-β) ligands, including myostatin and activin A. Here, we investigate the musculoskeletal effects of inhibiting activin A alone, myostatin alone, or both myostatin and activin A in wild-type (Wt) and heterozygous G610C (+/G610C) mice using specific monoclonal antibodies. Male and female Wt and +/G610C mice were treated twice weekly with intraperitoneal injections of monoclonal control antibody (Ctrl-Ab, Regn1945), anti-activin A antibody (ActA-Ab, Regn2476), anti-myostatin antibody (Mstn-Ab, Regn647), or both ActA-Ab and Mstn-Ab (Combo, Regn2476, and Regn647) from 5 to 16 weeks of age. Prior to euthanasia, whole body composition, metabolism and muscle force generation assessments were performed. Post euthanasia, hindlimb muscles were evaluated for mass, and femurs were evaluated for changes in microarchitecture and biomechanical strength using micro–computed tomography (μCT) and three-point bend analyses. ActA-Ab treatment minimally impacted the +/G610C musculoskeleton, and was detrimental to bone strength in male +/G610C mice. Mstn-Ab treatment, as previously reported, resulted in substantial increases in hindlimb muscle weights and overall body weights in Wt and male +/G610C mice, but had minimal skeletal impact in +/G610C mice. Conversely, the Combo treatment outperformed ActA-Ab alone or Mstn-Ab alone, consistently increasing hindlimb muscle and body weights regardless of sex or genotype and improving bone microarchitecture and strength in both male and female +/G610C and Wt mice. Combinatorial inhibition of activin A and myostatin more potently increased muscle mass and bone microarchitecture and strength than either antibody alone, recapturing most of the observed benefits of sActRIIB treatment in +/G610C mice. © 2022 American Society for Bone and Mineral Research (ASBMR). 相似文献
7.
8.
9.
Sebastian Bonner Thomas Matte Mitchell Rubin Joanne K Fagan Jennifer Ahern David Evans 《The Journal of asthma》2006,43(1):31-35
Although studies have documented underuse of controller medications and overuse of short-acting inhaled ss(2)-agonist among children with persistent asthma in disadvantaged communities, the persistence of oral ss(2)-agonist use in pediatric practice has not been studied since inhaled short-acting ss(2)-agonists became widespread. We describe medications used to treat asthma among children 3 to 5 years of age at 10 Head Start and other subsidized preschool centers in East and Central Harlem, New York City. We interviewed 149 parents/guardians of children who were identified as having probable asthma based on physician's diagnosis, persistent symptoms, hospitalization, and medication use. We classified 86 of the 149 children (58%) as having current persistent asthma. Only 15 of them (17%) were reported to have used controller medications at least 5 days/week in the last 4 weeks-only 2 of whom used inhaled corticosteroids. By contrast, 53 children (62%) used oral ss(2)-agonist in the last 4 weeks, often (72%) in conjunction with nebulized or inhaled short-acting ss(2)-agonist. Use of oral ss(2)-agonist was associated with more severe symptoms. This study documents the continued widespread use of oral ss(2)-agonist for treatment of children in a low-income community with high prevalence of asthma. 相似文献
10.